Navigation Links
Statins prevent cancer in heart transplant recipients
Date:5/20/2012

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

The research was presented at the Heart Failure Congress 2012, 19-22 May, in Belgrade, Serbia. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology.

Cancer is the leading cause of death late after heart transplantation. Skin cancer is particularly common, but solid organ cancers including colorectal cancer, prostate cancer and lymphoma also occur. The increased rate of cancer in heart transplant recipients may be related to the immune suppression of the patient.

Statins are immunomodulatory drugs and may benefit patients beyond their lipid lowering effects. The current study (abstract P306) investigated the impact of statin therapy on the occurrence of cancer and death from all causes in heart transplantation recipients.

The study included all 255 patients who underwent heart transplantation at the University Hospital Zurich in Switzerland between 1985 and 2007 and were alive after the first year. The primary endpoint was the occurrence of any cancer and the secondary endpoint was overall survival.

During follow up, cancer was diagnosed in 108 patients (42%). Statins reduced the risk of any cancer by 65% (p=0.0001). Eight years after transplantation the cumulative incidence of tumours was 34% in patients not receiving a statin compared to 13% in patients receiving a statin (p=0.003). The benefit persisted at the 10 year (39% vs. 18%) and 12 year follow-up (42% vs. 22%).

Statin use was associated with improved cancer free and overall survival (both p=0.0001). The beneficial effect of statins on preventing cancer and reducing death from all causes was independent of patients' cholesterol levels. This suggests that the benefit of statins was due to their immunomodulatory effects.

Guidelines from the International Society for Heart & Lung Transplantation (ISHLT) recommend giving a statin to patients after heart transplantation to reduce graft atherosclerosis. This study shows that there are additional benefits to following that recommendation.

Lead author Dr Frank Enseleit, deputy director of heart failure and transplantation at University Hospital Zurich, says patients can safely begin statin therapy six months after transplantation and they should take the drug for the rest of their lives.

"We have shown that statin therapy prevents cancer in heart transplant recipients and it is known that statins also prevent graft atherosclerosis," he says. "We have to conclude that it should be a lifelong therapy in heart transplant recipients."


'/>"/>

Contact: ESC Press Office
press@escardio.org
33-049-294-8627
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Statins May Benefit Prostate Cancer Patients
2. Alternative to Statins Shows Promise
3. Statins may slow progression of multiple sclerosis, new study finds
4. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
5. Do Statins Lower Male Sex Drive?
6. Statins Wont Lower Colon Cancer Risk
7. Statins decrease risk of clot-related diseases
8. Some statins have unintended effects and warrant closer monitoring, study finds
9. Too Many Stroke Patients Go Without Statins
10. MSU team studies connection between statins, tendon ruptures
11. Statins associated with lower cancer recurrence following prostatectomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... needy individuals and families from eight different sites throughout Miami-Dade and Broward counties. ... 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual meals ...
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
(Date:11/30/2016)... ... November 30, 2016 , ... "I hate when the mixture of ... my teeth," said an inventor from Bridgewater, N.J. "I thought that there had to ... device." , He developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from running ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... treatment has announced the opening of a new residential mental health treatment program ... mental health issues such as severe anxiety, depression, bi-polar disorder, and other related ...
(Date:11/30/2016)... ... November 30, 2016 , ... The Clinical ... that the FDA Binding Guidance goes into effect next month. Sponsors whose studies ... the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 bioLytical Laboratories, un líder mundial en test rápidos ... HIV Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la ...
(Date:12/2/2016)... DUBLIN , Dec 2, 2016 Research ... Market Size, Share, Development, Growth and Demand Forecast to 2022" report ... , , ... revenue of $6 billion in 2015, and it is expected to grow ... ultrasound segment is expected to witness faster growth during the forecast period, ...
(Date:12/2/2016)... , December 2, 2016 On ... Committee honored excellence in research, development and innovation in ... gala dinner was held in the presence of Sergey ... Russian Federation , Natalia Sanina, First ... Mikhail Murashko , Head of Roszdravnadzor, National Service of ...
Breaking Medicine Technology: